QuidelOrtho's China and Respiratory Reality Check

As IVD pricing guidelines widen and flu season looks soft, QuidelOrtho slashes guidance and pulls free-cash-flow guidance — while new CFO Micah Young works to turn the balance sheet around.

QDEL · Earnings Call · 2026-08-06

The China Rerating

QuidelOrtho's second-quarter results put a fine point on what changed since the prior call. Total revenue grew 2% constant-currency, but that was flattered by ex-China strength: labs ex-China +9%, immunohematology +5%, Triage +9%. China, by contrast, fell 23% year-over-year, and the language on the call was more cautious than we've heard before. CEO Brian Blaser said, “We are navigating significant headwinds in China and a softer respiratory environment, but the underlying performance of our business remains strong.” — Brian J. Blaser, President and Chief Executive Officer · 2026-08-06 But the driver of the shift isn't new — it's the IVD pricing guidelines, which have since become broader and more disruptive. The second draft, released in late June, eliminates methodology and use-case differentiation, expands the pilot from 3 to 6 provinces, and covers a wider product range. As Blaser put it, “The second draft of the IVD pricing guidelines, which was released for comment in late June, differs meaningfully from the preliminary draft issued in March.” — Brian J. Blaser, President and Chief Executive Officer · 2026-08-06 That is a meaningful escalation from the May call, when management still insisted, “We have no plans to walk away from China, and even after these changes are implemented, we believe the business continues to be accretive to our company margin profile.” — Brian J. Blaser, President and Chief Executive Officer · 2026-05-05 Now the strategy is defensive — protect the installed base, reduce inventories, and adapt commercial plans to a reimbursement environment that has yet to finalize its rules.

A Prudent Respiratory Assumption

The second leg of the guidance cut is respiratory. Positivity rates are down markedly versus 2025, and the Southern Hemisphere looks soft. Instead of assuming an average season, QuidelOrtho now models the second half on the lower end of historical seasons — a prudent approach that reduces the likelihood of a repeat over-delivery. This is a notable shift from the prior call, where management discussed planning around an average respiratory season. That change, combined with China, drove the full-year revenue guide down to $2.52–$2.6B, EBITDA to $540–$560M, and EPS to $0.65–$0.90. CFO Micah Young, in his first call, framed the move as a credibility play:

We are taking a disciplined approach to external cash-flow guidance while remaining intensely focused on execution and strengthening the balance sheet.
Micah Young, Chief Financial Officer · 2026-08-06

He also withdrew free-cash-flow guidance entirely, citing the combined working-capital uncertainty from China and respiratory seasonality.

Cash Conversion and the New CFO

The management team is now clearly prioritizing cash conversion and deleveraging over aggressive growth. With net debt leverage at 4.3x adjusted EBITDA, the balance sheet is stretched. But the stock has already priced in a lot of bad news: shares are up 6% over the trailing 90 days, though still down 95% from their 2020 peak. The install base and recurring revenue from labs and immunohematology remain the core value, and management continues to cite the Lex/Neulixa platform as a long-term growth option. Whether those assets can offset the structural pressures in China and respiratory is the central question, and the new CFO's focus on working capital and cost discipline is the promised remedy. Q2 already showed a 310bp EBITDA margin expansion to 20%, even in the seasonally weakest quarter, so the operational engine isn't broken — but the guide is now built on a much more sober view of the demand environment.